This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Hepatotoxicity has been associated with all forms of interferon beta.1 Autoimmune hepatitis (AIH), another hepatic complication of IFN (beta)-1a treatment for MS, has been reported.2 We present an unusual case.
A 52-year-old woman with a 10-year history of multiple sclerosis (MS) was initially treated with glatiramer acetate from 1997 to 1999. In January 2000, IFN beta-1a (Avonex) was started after relapsing symptoms occurred and new MRI lesions appeared. In December 2002, she developed painless jaundice, a cholecystectomy was performed, and her jaundice resolved. Avonex was continued. Hepatic function tests were normal in February 2003. IFN beta-1a (Rebif) was instituted in early May 2003 because of worsening gait and progressive MRI changes. The patient received 8.8 mcg SC (20% of target dose) every other day for only six doses until she noted increasing fatigue and jaundice. There was no history of acetaminophen, ethanol, or nefazodone use. Physical examination revealed marked jaundice. Laboratory tests showed increased hepatic enzymes and total bilirubin of 28.6 mg/dL (0.2 to 1.3 mg/dL). Hepatitis panel and thyroid function tests were normal.
ANA screen was positive in a 1:320 homogenous pattern. Anti-smooth antibodies were positive at 1:40 titer. A CT of the abdomen revealed no biliary obstruction. Prednisone 20 mg/day was administered. Over the next several months there was a dramatic decrease in jaundice and bilirubin levels, and by March 2004 the total bilirubin was 0.8 mg/dL.
Autoimmune complications have been reported in MS patients treated with interferon alpha and interferon beta after several months.2–4⇓⇓ The etiology of this immunologic complication is unclear but may involve disruption of vital intracellular functions, induction of antibody cytotoxicity, or mitochondrial …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
